Does EVEROLIMUS Cause Malignant neoplasm progression? 3,789 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 3,789 reports of Malignant neoplasm progression have been filed in association with EVEROLIMUS (EVEROLIMUS). This represents 9.6% of all adverse event reports for EVEROLIMUS.
3,789
Reports of Malignant neoplasm progression with EVEROLIMUS
9.6%
of all EVEROLIMUS reports
1,120
Deaths
1,076
Hospitalizations
How Dangerous Is Malignant neoplasm progression From EVEROLIMUS?
Of the 3,789 reports, 1,120 (29.6%) resulted in death, 1,076 (28.4%) required hospitalization, and 141 (3.7%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EVEROLIMUS. However, 3,789 reports have been filed with the FAERS database.
What Other Side Effects Does EVEROLIMUS Cause?
Death (5,090)
Diarrhoea (3,061)
Fatigue (2,946)
Stomatitis (2,692)
Nausea (2,079)
Dyspnoea (1,925)
Drug ineffective (1,837)
Pyrexia (1,664)
Decreased appetite (1,633)
Rash (1,603)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
OSIMERTINIB (2,920)
Which EVEROLIMUS Alternatives Have Lower Malignant neoplasm progression Risk?
EVEROLIMUS vs EVOLOCUMAB
EVEROLIMUS vs EXELON
EVEROLIMUS vs EXEMESTANE
EVEROLIMUS vs EXENATIDE
EVEROLIMUS vs EXFORGE